PT-141 (Bremelanotide)
Also known as: Bremelanotide, Vyleesi, PT141
Acts on desire in the brain rather than blood flow in the tissue — which is why it works where PDE5 inhibitors do not, and why nausea is the price most users pay.
Substance family
Peptides used for tendon, gut and skin repair. Mechanisms are described and animal data exists; controlled human trials for these applications largely do not.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Libido
AncillaryDose
0.5–1 mg, individual
Frequency
As needed, not daily
Cycle length
Single use, 45 minutes to several hours before
Start at the low end. Nausea is dose-dependent, and the difference between a tolerable dose and an unpleasant evening is small.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Nausea, sometimes severe
Countermeasure
The most common side effect by far and clearly dose-dependent. Lower the dose substantially; many find a fraction of the usual amount works with far less of it.
Problem
Blood pressure rises after dosing
Countermeasure
A documented effect. Relevant for anyone already running elevated pressure on cycle — worth knowing your baseline before adding something that pushes it further.
Problem
Flushing and darkening of moles or skin
Countermeasure
Melanocortin activity; related to what melanotan does deliberately. Less pronounced with PT-141, but present with repeated use.
Overview
PT-141 works on a different level than everything else used for this. Sildenafil and tadalafil act on blood vessels — they make an erection physically possible. PT-141 acts in the brain, on the pathways that produce desire in the first place.
That distinction is the entire point. It addresses the problem that a PDE5 inhibitor cannot touch: wanting to.
Mechanism of Action
It is an agonist at melanocortin receptors, principally MC4R, in the central nervous system. It is structurally a metabolite of melanotan II — the same family — but with far less of the pigmentation effect.
Because the mechanism is central rather than vascular, it also works independently of blood flow. Relevant where the cause is hormonal: crashed estradiol, elevated prolactin, or a suppressed axis after a cycle, all of which kill desire while leaving the plumbing intact.
Why the dose matters more than usual
Nausea is the defining side effect, it is dose-dependent, and the commonly quoted 1–2 mg is more than many people need.
Starting at 0.5 mg or below and increasing only if nothing happens costs one attempt. Starting at 2 mg because that is what a forum said costs an evening.
What it does not fix
If libido is gone because estradiol crashed, or prolactin is elevated, or the axis is suppressed post-cycle, then those are the problem and PT-141 is a workaround. It works — but it works around something that a blood test would identify and that has its own solution.
Using it to paper over a hormonal problem for months is the same error as suppressing a resting heart rate: the warning goes, the cause stays.
Side Effects & Risks
- Nausea — common, sometimes severe, strongly dose-dependent
- Raised blood pressure for a few hours after dosing
- Flushing, headache
- Darkening of moles and freckles with repeated use
- Injection site reactions
Blood Work & Monitoring
- Blood pressure — know your baseline, especially on cycle
- Estradiol (sensitive), prolactin, total testosterone — to check whether the underlying cause is something treatable in itself
Harm-Reduction Notes
- Start well below the commonly quoted dose; nausea is the limiting factor and it is avoidable
- Not for someone already running high blood pressure without knowing where they stand
- Occasional use, not daily
- Sold as a research chemical almost everywhere, with the purity and dosing uncertainty that implies
- If libido is gone on cycle, test before treating — the answer is often hormonal and fixable at the source
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Approved for one indication, otherwise off-labelApproved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. |
| EU / UK | Not broadly approvedCirculates as a research chemical without pharmaceutical oversight. |
| Canada / Australia | Restricted |
| Parts of Asia, Latin America & Middle East | Availability varies |
| Competitive sport | Check the current WADA list |